Magnus Bäck1. 1. INSERM U698, Bichat Hospital, 46 rue Henri Huchard, 75018, Paris, France. Magnus.Back@ki.se
Abstract
INTRODUCTION: The inflammatory process of atherosclerosis is associated with several pathophysiological reactions within the vascular wall. The arachidonic acid released by phospholipase A(2) serves as substrate for the production of a group of lipid mediators known as the leukotrienes, which induce pro-inflammatory signaling through activation of specific BLT and CysLT receptors. DISCUSSION: Leukotriene signaling has been implicated in early lipid retention and foam cell accumulation, as well as in the development of intimal hyperplasia and advanced atherosclerotic lesions. Furthermore, the association of leukotrienes with degradation of extracellular matrix has suggested a role in atherosclerotic plaque rupture. Finally, studies of either myocardial or cerebral ischemia and reperfusion indicate that leukotriene signaling in addition may be involved in the development of ischemic injury. CONCLUSION: Both leukotriene synthesis inhibitors and leukotriene receptor antagonists have been suggested to induce beneficial effects at different stages of the atherosclerosis process.
INTRODUCTION: The inflammatory process of atherosclerosis is associated with several pathophysiological reactions within the vascular wall. The arachidonic acid released by phospholipase A(2) serves as substrate for the production of a group of lipid mediators known as the leukotrienes, which induce pro-inflammatory signaling through activation of specific BLT and CysLT receptors. DISCUSSION: Leukotriene signaling has been implicated in early lipid retention and foam cell accumulation, as well as in the development of intimal hyperplasia and advanced atherosclerotic lesions. Furthermore, the association of leukotrienes with degradation of extracellular matrix has suggested a role in atherosclerotic plaque rupture. Finally, studies of either myocardial or cerebral ischemia and reperfusion indicate that leukotriene signaling in addition may be involved in the development of ischemic injury. CONCLUSION: Both leukotriene synthesis inhibitors and leukotriene receptor antagonists have been suggested to induce beneficial effects at different stages of the atherosclerosis process.
Authors: Magnus Bäck; De-xiu Bu; Robert Bränström; Yuri Sheikine; Zhong-Qun Yan; Göran K Hansson Journal: Proc Natl Acad Sci U S A Date: 2005-11-17 Impact factor: 11.205
Authors: Charles Brink; Sven-Erik Dahlén; Jeffrey Drazen; Jilly F Evans; Douglas W P Hay; Simonetta Nicosia; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo Journal: Pharmacol Rev Date: 2003-03 Impact factor: 25.468
Authors: F Wunder; H Tinel; R Kast; A Geerts; E M Becker; P Kolkhof; J Hütter; J Ergüden; M Härter Journal: Br J Pharmacol Date: 2010-05 Impact factor: 8.739
Authors: Gretchen Bain; Christopher D King; Kevin Schaab; Melissa Rewolinski; Virginia Norris; Claire Ambery; Jane Bentley; Masanori Yamada; Angelina M Santini; Jeroen van de Wetering de Rooij; Nicholas Stock; Jasmine Zunic; John H Hutchinson; Jilly F Evans Journal: Br J Clin Pharmacol Date: 2013-03 Impact factor: 4.335
Authors: Piotr Ruchala; Mohamad Navab; Chun-Ling Jung; Susan Hama-Levy; Ewa D Micewicz; Hai Luong; Jonathan E Reyles; Shantanu Sharma; Alan J Waring; Alan M Fogelman; Robert I Lehrer Journal: PLoS One Date: 2010-04-14 Impact factor: 3.240